217 related articles for article (PubMed ID: 28235541)
1. Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
Gutteridge RE; Singh CK; Ndiaye MA; Ahmad N
Cancer Lett; 2017 May; 394():13-21. PubMed ID: 28235541
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
3. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.
Schmit TL; Zhong W; Setaluri V; Spiegelman VS; Ahmad N
J Invest Dermatol; 2009 Dec; 129(12):2843-53. PubMed ID: 19554017
[TBL] [Abstract][Full Text] [Related]
4. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
Zhang Z; Zhang G; Gao Z; Li S; Li Z; Bi J; Liu X; Li Z; Kong C
BMC Cancer; 2017 Dec; 17(1):861. PubMed ID: 29246203
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
Kim HJ; Cho JH; Kim JR
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
[TBL] [Abstract][Full Text] [Related]
9. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of PLK1 inhibits invasion and promotes apoptosis in glioma cells through regulating autophagy.
Wu ZY; Wei N
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2723-2733. PubMed ID: 29771424
[TBL] [Abstract][Full Text] [Related]
11. PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.
Su S; Chhabra G; Ndiaye MA; Singh CK; Ye T; Huang W; Dewey CN; Setaluri V; Ahmad N
Mol Cancer Ther; 2021 Jan; 20(1):161-172. PubMed ID: 33177155
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
13. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
Zhang J; Wang S; Kern S; Cui X; Danner RL
J Biol Chem; 2007 Jan; 282(2):1003-9. PubMed ID: 17121839
[TBL] [Abstract][Full Text] [Related]
17. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.
Schmit TL; Zhong W; Nihal M; Ahmad N
Cell Cycle; 2009 Sep; 8(17):2697-702. PubMed ID: 19652546
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic relevance of the protein phosphatase 2A in cancer.
Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 expression is a prognostic factor in human colon cancer.
Weichert W; Kristiansen G; Schmidt M; Gekeler V; Noske A; Niesporek S; Dietel M; Denkert C
World J Gastroenterol; 2005 Sep; 11(36):5644-50. PubMed ID: 16237758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
